Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSCEI June 2026 Index Rebalance: Post-Announcement Positioning

HSCEI Index Rebalance: March 2026 Post-Event Review

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>HSCEI June 2026 implementation takes effect on 8 Jun 2026, with Hansoh and Akeso as ADDs and Sunny Optical and Haier Smart Home as DELETEs.</li>
<li>Both ADDs declined through the bridge while DELETE names rose over the same period.</li>
<li>Historical first-week outcomes for negative-bridge ADDs were weak while positive-bridge DELETEs kept a positive first-week bias.</li>
</ul>


HSCEI June 2026 implementation takes effect on 8 Jun 2026, with Hansoh and Akeso as ADDs and Sunny Optical and Haier Smart Home as DELETEs.
Both ADDs declined through the bridge while DELETE names rose over the same period.
Historical first-week outcomes for negative-bridge ADDs were weak while positive-bridge DELETEs kept a positive first-week bias.


HSCEI June 2026 Index Rebalance: Pre-Implementation Update

Hansoh Pharmaceutical

HSCEI June 2026 Index Rebalance: Pre-Implementation Update